These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease. Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944 [TBL] [Abstract][Full Text] [Related]
9. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients. Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients. Jamal AJ; Husain S; Li Y; Famure O; Kim SJ Transplantation; 2014 Mar; 97(5):569-75. PubMed ID: 24398852 [TBL] [Abstract][Full Text] [Related]
12. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study. Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487 [TBL] [Abstract][Full Text] [Related]
13. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644 [TBL] [Abstract][Full Text] [Related]
14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Shah T; Lai WK; Mutimer D Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091 [TBL] [Abstract][Full Text] [Related]
15. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139 [TBL] [Abstract][Full Text] [Related]
16. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019 [TBL] [Abstract][Full Text] [Related]